New drug candidate BR101801 tested in advanced blood cancers
NCT ID NCT04018248
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested an experimental drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to prior treatments. The main goals were to find a safe dose and check for side effects. The study is complete, but it is too early to know if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BR101801 (an experimental drug taken as capsules)
- What this could lead to
- If it works, this could point toward a new treatment option for certain advanced blood cancers that have not responded to other therapies.
- What could go wrong
- This is a very early Phase I trial with only 26 participants, so it is primarily testing safety and dosing, not effectiveness. The drug may not work or could have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, South Korea
-
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Inje University Busan Paik Hospital
Busan, South Korea
-
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
-
Seoul national university hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?